Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Avinash Reddy

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
World Journal of Translational Medicine|December 20, 2014
Epithelial ovarian cancer: An overviewArpita Desai, Jingyao Xu, Kartik Aysola, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2020
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived XenograftsAlbert Gris-Oliver, Marta Palafox, Laia Monserrat, et al.
Nature Medicine|February 13, 2024
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trialBenjamin Besse, Elvire Pons-Tostivint, Keunchil Park, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
World Journal of Translational Medicine|December 20, 2014
Epithelial ovarian cancer: An overviewArpita Desai, Jingyao Xu, Kartik Aysola, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2020
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived XenograftsAlbert Gris-Oliver, Marta Palafox, Laia Monserrat, et al.
Nature Medicine|February 13, 2024
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trialBenjamin Besse, Elvire Pons-Tostivint, Keunchil Park, et al.
Pageof 4